Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 9:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 1,416 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active capsule Clear all
Not listed Phase 1 Interventional Accepts healthy volunteers

Determination of Safety,Tolerability,Pharmacokinetics,Food Effect& Pharmacodynamics of Single & Multiple Doses of P11187

NCT01874366
View directory record Official record
Conditions
Overweight, Diabetes Mellitus Type 2 in Obese
Interventions
P11187, Placebo
Drug
Lead sponsor
Piramal Enterprises Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced Oct 27, 2026, 9:48 AM EDT
Completed Phase 2 Interventional Results available

AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)

NCT02141672
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Voclosporin High Dose, Voclosporin Low Dose, Placebo
Drug
Lead sponsor
Aurinia Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
14
States / cities
Los Angeles, California • Palo Alto, California • Gainesville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Oct 27, 2026, 9:48 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease

NCT05771428
View directory record Official record
Conditions
Alzheimer's Disease (AD)
Interventions
ABBV-552, Placebo for ABBV-552
Drug
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 90 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
37
States / cities
Irvine, California • Long Beach, California • Los Alamitos, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 27, 2026, 9:48 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Protection From Acute Kidney Injury (AKI) With Basis™ Treatment

NCT04342975
View directory record Official record
Conditions
AKI
Interventions
Nicotinamide Riboside + Pterostilbene, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 27, 2026, 9:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Astaxanthin in Healthy Participants

NCT05376501
View directory record Official record
Conditions
Healthy
Interventions
Astaxanthin, Placebo
Dietary Supplement · Other
Lead sponsor
LycoRed Ltd.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Oct 27, 2026, 9:48 AM EDT
Completed Not applicable Interventional Results available

Effect of Dietary Glycemic Index on Beta-cell Function

NCT01386645
View directory record Official record
Conditions
Impaired Glucose Tolerance, Oxidative Stress, Prediabetes, Impaired Fasting Glucose
Interventions
low glycemic index (LGI) diet, high glycemic index (HGI) diet plus placebo (PLAC), high glycemic index diet plus N-acetylcysteine
Other · Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Oct 27, 2026, 9:48 AM EDT
Completed Not applicable Interventional

A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir

NCT00000892
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Nelfinavir mesylate, Levocarnitine, Adefovir dipivoxil, Saquinavir, Delavirdine mesylate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
45
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 27, 2026, 9:48 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Exparel Use in Adductor Canal Block After Total Knee Arthroplasty

NCT04910165
View directory record Official record
Conditions
Arthritis Knee, Pain, Postoperative, Opioid Use
Interventions
Exparel, Ropivacaine
Drug
Lead sponsor
St. Luke's Hospital, Pennsylvania
Other
Eligibility
18 Years to 99 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 20, 2022 · Synced Oct 27, 2026, 9:48 AM EDT
Completed Phase 3 Interventional Results available

PALISADE Follow-on Study (ARC004)

NCT02993107
View directory record Official record
Conditions
Peanut Allergy
Interventions
AR101
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 55 Years
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
47
States / cities
Tucson, Arizona • Little Rock, Arkansas • Mission Viejo, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Oct 27, 2026, 9:48 AM EDT
Completed Phase 2 Interventional Results available

Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants

NCT02243202
View directory record Official record
Conditions
Obesity
Interventions
Canagliflozin, Phentermine, Matching Placebo to Canagliflozin, Matching Placebo to Phentermine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
17
States / cities
Phoenix, Arizona • Walnut Creek, California • Jacksonville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Oct 27, 2026, 9:48 AM EDT
Terminated Phase 2 Interventional Results available

Effects of ABT-089 on Smoking Abstinence Symptoms and Reward

NCT01756053
View directory record Official record
Conditions
Nicotine Addiction
Interventions
ABT-089, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2014 · Synced Oct 27, 2026, 9:48 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

LDX for the Treatment of Cognitive Functioning Issues in Women Post-Oophorectomy

NCT01986777
View directory record Official record
Conditions
Cognitive Impairments, RRSO
Interventions
lisdexamfetamine, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
30 Years to 60 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Oct 27, 2026, 9:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Capsule Endoscopy for HEmorrhage in the ER

NCT03458000
View directory record Official record
Conditions
Upper Gastrointestinal Bleeding
Interventions
PillCam UGI, Standard of Care
Device · Other
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Durham, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Oct 27, 2026, 9:48 AM EDT
Completed Not applicable Interventional

RESTORE ME -- RCT of Oxaloacetate on Improving Fatigue in ME/CFS

NCT05273372
View directory record Official record
Conditions
Myalgic Encephalomyelitis, Chronic Fatigue Syndrome, Fatigue
Interventions
Placebo, Medical Food - Anhydrous Enol-Oxaloacetate
Other
Lead sponsor
Terra Biological LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 27, 2026, 9:48 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency

NCT00662675
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency, Steatorrhea, Malabsorption Syndromes, Cystic Fibrosis
Interventions
Pancrease MT 10.5, or MT 21, Placebo for Pancrease MT 10.5 or MT 21
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
7 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
Long Beach, California • Los Angeles, California • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 27, 2026, 9:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Glyceryl Tribenzoate (GTB) Capsules in Healthy Subjects

NCT05938452
View directory record Official record
Conditions
Neurological Disorder
Interventions
Glyceryl Tribenzoate
Drug
Lead sponsor
Forest Hills Lab
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Bloomfield, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 27, 2026, 9:48 AM EDT
Completed Phase 3 Interventional Results available

A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial

NCT01727726
View directory record Official record
Conditions
Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
Interventions
Brexpiprazole, Seroquel XR, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
2,182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
44
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2018 · Synced Oct 27, 2026, 9:48 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents

NCT00915655
View directory record Official record
Conditions
HIV-1 Infection
Interventions
darunavir, ritonavir, zidovudine, lamivudine, abacavir
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
12 Years to 18 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 27, 2026, 9:48 AM EDT
Completed Phase 4 Interventional Results available

Modulation of Esophageal Inflammation in Barrett's Esophagus by Omega-3 Fatty Acids

NCT01733147
View directory record Official record
Conditions
Barrett's Esophagus, Obesity
Interventions
Omega-3 polyunsaturated fatty acids, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 27, 2026, 9:48 AM EDT
Recruiting Phase 1 Interventional

Study to Evaluate the Fecal Microbiota Transplantation (FMT) in the Treatment of Ulcerative Colitis

NCT05786404
View directory record Official record
Conditions
Active Ulcerative Colitis (UC)
Interventions
PRIM-DJ2727 - FROZEN, PRIM-DJ2727 - CAPSULES
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Oct 27, 2026, 9:48 AM EDT
Enrolling by invitation Not applicable Interventional

NAD Supplementation in Parkinson's Disease

NCT07703137
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Nicotinamide Riboside (NR), Oral placebo capsules
Dietary Supplement
Lead sponsor
University of Oklahoma
Other
Eligibility
55 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 27, 2026, 9:48 AM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Methylphenidate in Improving Cognition and Function in Older Adults With Depression

NCT00602290
View directory record Official record
Conditions
Depression
Interventions
Citalopram, Methylphenidate (MPH), Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
60 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Oct 27, 2026, 9:48 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Exercise, Milk Thistle, and Lactobacillus to Influence Plasma Bilirubin

NCT04717726
View directory record Official record
Conditions
Obesity
Interventions
Milk Thistle (MT), Lactobacillus Gasseri (LAC), Exercise (EX), Control (CON)
Dietary Supplement · Behavioral
Lead sponsor
Kyle Flack
Other
Eligibility
18 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 27, 2026, 9:48 AM EDT
Recruiting Phase 3 Interventional

A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial)

NCT06150560
View directory record Official record
Conditions
Coarctation of Aorta, High Blood Pressure
Interventions
Losartan, Amlodipine, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 27, 2026, 9:48 AM EDT